Advertisement
Advertisement

BCRX

BCRX logo

BioCryst Pharmaceuticals Inc

6.38
USD
Sponsored
+0.14
+2.32%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

6.33

-0.05
-0.86%

BCRX Earnings Reports

Positive Surprise Ratio

BCRX beat 22 of 40 last estimates.

55%

Next Report

Date of Next Report
Feb 26, 2026
Estimate for Q4 25 (Revenue/ EPS)
$154.35M
/
$0.04
Implied change from Q3 25 (Revenue/ EPS)
-3.16%
/
-33.33%
Implied change from Q4 24 (Revenue/ EPS)
+17.35%
/
-130.77%

BioCryst Pharmaceuticals Inc earnings per share and revenue

On Nov 03, 2025, BCRX reported earnings of 0.06 USD per share (EPS) for Q3 25, beating the estimate of 0.03 USD, resulting in a 67.13% surprise. Revenue reached 159.40 million, compared to an expected 166.23 million, with a -4.11% difference. The market reacted with a -6.28% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 13 analysts forecast an EPS of 0.04 USD, with revenue projected to reach 154.35 million USD, implying an decrease of -33.33% EPS, and decrease of -3.16% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, BioCryst Pharmaceuticals Inc reported EPS of $0.06, beating estimates by 67.13%, and revenue of $159.40M, -4.11% below expectations.
The stock price moved down -6.28%, changed from $7.32 before the earnings release to $6.86 the day after.
The next earning report is scheduled for Feb 26, 2026.
Based on 13 analysts, BioCryst Pharmaceuticals Inc is expected to report EPS of $0.04 and revenue of $154.35M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement